Friday, July 3, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
DEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its RivalstodayENERGYThe Interconnect Loser: Why FERC's Co-Location Ruling Could Squeeze Merchant Nuclear Margins4 weeks agoDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's ExpensetodayHEALTHCAREGLP-1 Coverage Mandate: The Federal Obesity Drug Windfall for Lilly and Novo4 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Suppliers on Notice — and Hands Clean-Label Brands a Marketing EdgetodayENERGYVistra vs. Constellation: Same Nuclear Tax Credit, Very Different Downside if Congress Kills It4 weeks agoENERGYThe US-Iran Ceasefire Deal Opens a 60-Day Clock — and a Potential Oil Supply Shock That Hits Energy StockstodayHEALTHCAREFDA Accelerated Approval Reform: The Vertex Model Every Biotech Wants4 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential CustomerstodayENERGYTalen Energy: The Merchant Nuclear Stock That Only Washington Can Break4 weeks agoCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most RisktodayHEALTHCAREThe Medicare Drug Negotiation Trade: Who Gets Hurt When Washington Sets the Price4 weeks agoENERGYFederal Radiation Rule Overhaul Is the Regulatory Unlock Nuclear Power Has Been Waiting FortodayENERGYBWXT: The Naval Nuclear Contractor Riding a Civilian Policy Wave4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger MarkettodayENERGYThe NRC Discount Helps Oklo More Than NuScale — Because NuScale Already Paid Full Price4 weeks agoWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity StacktodayCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big TechyesterdayENERGYForget Which Reactor Wins — GE Vernova Owns the Queue4 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets PaidyesterdayCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger MarketyesterdayCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending BoomyesterdayENERGYCentrus vs. Cameco: Washington's Russian Uranium Ban Splits the Nuclear Fuel Chain4 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real MoneyyesterdayENERGYThe HALEU Contract Nobody Prices In4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is MovingyesterdayCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet TailwindyesterdayENERGYWhy Constellation (CEG) Is Really a Policy Stock, Not a Utility Stock4 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company ForeveryesterdayCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners4 weeks agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock2 days agoCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It4 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch2 days agoENERGYWillow Isn't an Oil Play. It's an Interior Department Play.4 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political2 days agoCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade3 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers2 days agoENERGYWho Gets Exposed When the SPR Refill Never Happens3 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending2 days agoENERGYWashington Fixed the LNG Permit. It Can't Fix a County Courthouse in Guilford County.3 weeks agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game2 days agoENERGYThe Jones Act's Hidden LNG Winner: Foreign Tankers, Not U.S. Shippers, Cash In3 weeks agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk3 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model3 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade3 days agoENERGYHalliburton vs. SLB: Who Actually Cashes In on Methane Compliance3 weeks agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet4 days agoENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.3 weeks agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX4 days agoTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation4 days agoTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream4 days agoENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog3 weeks agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides5 days agoTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It5 days agoENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners3 weeks agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine6 days agoTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order6 days agoTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program6 days agoENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock3 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes6 days agoENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll3 weeks agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenlylast weekTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oillast weekDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First3 weeks agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differentlylast weekTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekDEFENSEThe Refueling Line Nobody Prices Into BWXT3 weeks agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivotlast weekDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price3 weeks agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Throughlast weekENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers3 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two3 weeks agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat2 weeks agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Storylast weekENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom2 weeks agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguiselast weekDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch2 weeks agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes2 weeks agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratoslast weekDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization2 weeks agoDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Betlast weekENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear2 weeks agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch2 weeks agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast weekDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop2 weeks agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washingtonlast weekENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hublast weekDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One2 weeks agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spendinglast weekDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money2 weeks agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Primelast weekENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors2 weeks agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alivelast weekENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus2 weeks agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AIlast week
That's your last free article this week. Create a free account for 2 a week — or go Pro for everything.Go Pro →
Healthcare & FDA

Medicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers

Federal coverage of Wegovy and similar drugs through Medicare is the single largest demand expansion in the GLP-1 market's history.

Image: Money Racket
By at Money Racket · Jul 3, 2026

Medicare began covering weight-loss drugs including Wegovy for eligible beneficiaries on July 1, 2026, through a GLP-1 Bridge program, according to CNN and Pharmaceutical Executive. This marks the first time Medicare has covered drugs specifically for weight loss, opening the program's roughly 67 million enrollees to these therapies.

Who cashes in: Novo Nordisk (NVO) makes Wegovy (semaglutide) and is the most direct beneficiary — Medicare coverage removes the single biggest access barrier for the drug's largest potential patient cohort. Eli Lilly (LLY) makes Zepbound (tirzepatide), the competing GLP-1 that will also be eligible; both companies stand to see volume increases that dwarf anything the commercial market has delivered. The supply chain behind these drugs also benefits: West Pharmaceutical Services (WST) and Gerresheimer (private/German) make the injectable delivery systems, and Catalent (now part of Novo's supply chain) handles fill-finish manufacturing. On the plastics and packaging side, Plastics News has flagged a manufacturing boost for GLP-1 production components.

Medicare coverage of GLP-1s is not incremental — it is the largest single expansion of the addressable market these drugs have ever seen.

Who's exposed: The Trump administration has separately proposed a rule it says could save Medicare patients $1.1 billion on drugs — if that rule includes GLP-1 pricing pressure, it could compress the net revenue per prescription even as volume rises. Compounding pharmacies that have been filling semaglutide during the shortage period face a more competitive landscape as branded supply expands to meet Medicare demand. Weight-loss surgery providers and bariatric device makers like Intuity Medical face long-term volume pressure as pharmacological alternatives become more accessible.

What to watch: CMS reimbursement rates for GLP-1s under Medicare Part D and whether the proposed drug-pricing rule applies to this class. The rate set by CMS will determine how much of the volume gain actually flows to Novo and Lilly's bottom lines.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →